# ProLigna (Pinus sylvestris)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/proligna
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Pinus sylvestris extract, Scots pine extract, Scotch pine extract, European pine extract, Pine sylvestris, Scots fir, Norway pine, Red pine, Baltic pine, Kiefer extract, Pin sylvestre, Sosna zwyczajna extract

## Overview

ProLigna is a standardized extract from Pinus sylvestris (Scots pine) knot wood, concentrated in stilbene compounds—primarily pinosylvin and pinosylvin monomethyl ether—that inhibit [pro-inflammatory cytokine](/ingredients/condition/inflammation) expression. These bioactives act on NF-κB signaling pathways and exhibit [antimicrobial](/ingredients/condition/immune-support) activity, forming the biochemical basis for its immune and respiratory support applications.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) support: Pinosylvin compounds from P. sylvestris knots showed reduction in inflammatory gene expression (in vitro evidence only)
• Traditional respiratory support: Historically used for bronchitis treatment (traditional use only, no clinical trials)
• Antiseptic properties: Traditional medicinal applications note antiseptic effects (no human studies available)
• Expectorant action: Folk medicine use for respiratory conditions (traditional evidence only)
• Potential [immune modulation](/ingredients/condition/immune-support): Categorized as immune support ingredient (no clinical validation identified)

## Mechanism of Action

Pinosylvin and pinosylvin monomethyl ether, the primary stilbene compounds in Pinus sylvestris knot extract, suppress NF-κB nuclear translocation, thereby reducing transcription of pro-inflammatory genes including COX-2, TNF-α, and IL-6. These compounds also inhibit lipoxygenase (LOX) enzymes involved in leukotriene synthesis, contributing to their [anti-inflammatory](/ingredients/condition/inflammation) profile. Additionally, pinosylvin disrupts microbial cell membrane integrity, accounting for the observed antiseptic and antifungal properties documented in laboratory studies.

## Clinical Summary

Evidence for ProLigna and Pinus sylvestris knot extract remains predominantly preclinical. In vitro studies using human cell lines have demonstrated measurable reductions in [inflammatory](/ingredients/condition/inflammation) gene expression following pinosylvin exposure, but no peer-reviewed randomized controlled trials with human participants have established clinical efficacy or therapeutic dosing. Traditional use records support respiratory applications such as bronchitis relief, though these lack the methodological rigor of clinical investigation. Overall, the evidence base is considered preliminary, and claims of benefit in humans should be interpreted cautiously until controlled trials are conducted.

## Nutritional Profile

ProLigna is a proprietary extract derived from Pinus sylvestris (Scots pine) knot wood and is not a conventional food source; therefore, standard macronutrient values (protein, fat, carbohydrate, fiber) are negligible or not applicable. Its value lies entirely in its bioactive phytochemical profile. Key bioactive compounds include: • Pinosylvin (3,5-dihydroxy-trans-stilbene): A stilbenoid polyphenol and the primary active constituent, typically concentrated in heartwood and knot tissue at approximately 2–5% of dry knot weight (~20–50 mg/g dry weight); structurally related to resveratrol but with distinct bioactivity; exhibits [antimicrobial](/ingredients/condition/immune-support), antifungal, and [anti-inflammatory](/ingredients/condition/inflammation) properties in preclinical models. • Pinosylvin monomethyl ether (PSME): A methylated derivative of pinosylvin, present at approximately 1–3% of dry knot weight (~10–30 mg/g); may have enhanced lipophilicity and membrane permeability compared to pinosylvin. • Pinosylvin dimethyl ether (PSDME): Present in lower concentrations (~0.5–1.5% of dry knot weight); further methylation may influence metabolic stability. • Resin acids (abietic acid, dehydroabietic acid, isopimaric acid): Present in the oleoresin fraction at variable concentrations (~5–15% of crude extract depending on processing); some show modest anti-inflammatory and antimicrobial activity in vitro. • Lignans (nortrachelogenin/hydroxymatairesinol): Found in Scots pine knots at approximately 5–10% of dry knot weight (~50–100 mg/g); these are phytoestrogenic compounds with [antioxidant](/ingredients/condition/antioxidant) properties; bioavailability is moderate, with gut microbiota-mediated conversion to enterolignans (enterodiol, enterolactone). • Flavonoids (pinocembrin, pinobanksin, chrysin): Present in minor amounts (~0.1–1% of extract); pinocembrin has demonstrated [neuroprotective](/ingredients/condition/cognitive) and anti-inflammatory effects in preclinical studies. • Essential oil terpenes (α-pinene, β-pinene, limonene, δ-3-carene): Volatile monoterpenes contributing to traditional respiratory/expectorant applications; concentrations are highly variable depending on extraction method. Micronutrient content: Trace minerals including manganese, zinc, and iron may be present in negligible amounts from the wood matrix but are not considered nutritionally significant. Bioavailability notes: Stilbenoids such as pinosylvin have limited oral bioavailability due to rapid phase II [metabolism](/ingredients/condition/weight-management) (glucuronidation and sulfation) in the liver and intestine, analogous to resveratrol (estimated oral bioavailability <5–10% for free aglycone form). Lignans require colonic microbial metabolism for conversion to bioactive enterolignans, with significant inter-individual variability depending on [gut microbiome](/ingredients/condition/gut-health) composition. Resin acids are relatively lipophilic and may benefit from co-administration with dietary fats. No standardized nutritional facts panel exists, as ProLigna is classified as a botanical extract/supplement rather than a food.

## Dosage & Preparation

No clinically studied dosage ranges for ProLigna or Pinus sylvestris extracts in humans are available, as no relevant clinical trials exist. Traditional or product-specific standardization details are not provided in the research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

ProLigna and Pinus sylvestris extracts have no well-documented serious adverse effects at typical supplemental doses, but systematic human safety trials are absent, limiting definitive conclusions. Pinosylvin shares structural similarities with resveratrol and may theoretically potentiate anticoagulant medications such as warfarin or aspirin by inhibiting platelet aggregation pathways—though this interaction has not been confirmed clinically. Individuals with pine or conifer allergies should avoid use due to potential cross-reactivity with pine pollen or resin components. Pregnant and breastfeeding women should avoid supplementation given the complete absence of safety data in these populations.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on ProLigna or standardized Pinus sylvestris extracts were identified in the available research. The only study referenced examines pinosylvin compounds showing [anti-inflammatory](/ingredients/condition/inflammation) effects in vitro, but lacks human trial data, sample sizes, or clinical outcomes.

## Historical & Cultural Context

Pinus sylvestris has a documented history in European folk medicine for treating bronchitis and serving as an antiseptic, diuretic, and expectorant using leaves and young shoots. Turpentine derived from the resin has additional traditional medicinal applications spanning European herbal systems.

## Synergistic Combinations

Echinacea, Elderberry, Vitamin C, Zinc, Astragalus

## Frequently Asked Questions

### What is pinosylvin and why does it matter in ProLigna?

Pinosylvin is a naturally occurring stilbene compound concentrated in the knot wood of Pinus sylvestris and is the principal bioactive in ProLigna extracts. It functions similarly to resveratrol by inhibiting NF-κB-driven inflammatory gene transcription and demonstrating antimicrobial activity against gram-positive bacteria and fungi in laboratory settings. Standardized ProLigna extracts are typically characterized by their pinosylvin and pinosylvin monomethyl ether content to ensure consistent potency.

### Is there clinical trial evidence supporting ProLigna for immune support?

As of current literature, no published randomized controlled trials have evaluated ProLigna specifically in human subjects for immune outcomes. Available support comes from in vitro cell studies showing reduced expression of inflammatory markers like TNF-α and IL-6, alongside historical ethnobotanical use of Scots pine for respiratory ailments. Consumers should treat immune support claims as preliminary until human clinical data are available.

### How does ProLigna differ from standard pine bark extract (Pycnogenol)?

ProLigna is derived from the knot wood of Pinus sylvestris and is standardized for stilbene compounds, chiefly pinosylvin, whereas Pycnogenol is extracted from the bark of Pinus pinaster and is standardized for oligomeric proanthocyanidins (OPCs). These represent chemically distinct compound classes with different primary mechanisms—pinosylvins modulate NF-κB and LOX pathways, while OPCs act more prominently as direct antioxidants and support endothelial nitric oxide production. Clinical evidence for Pycnogenol is substantially more robust than for ProLigna.

### What is the typical dosage of ProLigna supplement?

No clinically validated dosage range has been established for ProLigna because human dose-finding trials have not been published. Manufacturer-suggested doses for Pinus sylvestris knot extracts generally range from 100 to 300 mg per day of standardized extract, with pinosylvin content typically specified on labels. Without clinical pharmacokinetic data in humans, these figures are based on traditional use guidance and in vitro effective concentrations rather than evidence-based dosing protocols.

### Can ProLigna interact with blood thinners or other medications?

Pinosylvin's structural resemblance to resveratrol raises a theoretical concern that it could inhibit platelet aggregation and potentiate anticoagulants such as warfarin, heparin, or antiplatelet agents like clopidogrel, though no confirmed drug interaction studies exist. Individuals taking cytochrome P450-metabolized medications should exercise caution, as stilbene compounds can modulate CYP enzyme activity in vitro. Until human pharmacokinetic and drug interaction data are available, consultation with a healthcare provider is advisable before combining ProLigna with prescription medications.

### Is ProLigna safe to use during pregnancy and breastfeeding?

There is insufficient clinical evidence regarding ProLigna's safety during pregnancy and breastfeeding, as no human studies have been conducted in these populations. Due to the limited safety data and traditional use context, pregnant or nursing women should consult their healthcare provider before using ProLigna supplements. This precautionary approach is standard for botanical ingredients lacking specific pregnancy/lactation safety trials.

### What is the quality of evidence supporting ProLigna's traditional respiratory benefits?

ProLigna's historical use for bronchitis and respiratory support is based on traditional medicinal applications rather than modern clinical trials in humans. While in vitro studies have shown pinosylvin compounds may have anti-inflammatory properties relevant to respiratory health, these laboratory findings have not been confirmed in controlled human studies. The evidence level is considered traditional/historical use rather than clinically validated.

### Who is most likely to benefit from ProLigna supplementation based on current evidence?

ProLigna may be most relevant for individuals seeking general immune and inflammatory support, as this is where the strongest preliminary in vitro evidence exists for its pinosylvin content. Those interested in traditional respiratory wellness support may also consider it, though this application lacks clinical validation. Individuals already taking anticoagulants or those with bleeding disorders should avoid ProLigna without medical guidance due to potential interaction risks.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*